Androgens are implicated in the development of prostate cancer (CAP) and benign prostate hyperplasia. The conversion of testosterone to the more potent metabolite dihydrotestosterone by prostatespecific steroid 5␣-reductase type 2 (5␣-red2) is a key mechanism in the action of androgens in the prostate and is important in the promotion and progression of prostate diseases. Manipulation of the turnover of androgens is thus fundamental in the pharmacological treatment strategy.
D
URING the last 10 yr, diseases of the prostate have attracted increasing interest among urologists and the scientific community. Behind this interest is our knowledge of the large impact of prostatic disorders on the general health of the male population and on health care costs. Symptomatic benign prostate hyperplasia (BPH) is found in more than 40% of the aging male population (1) , and prostatic cancer (CAP) is the most common malignancy in males (2) . In addition, novel treatment possibilities for both BPH and CAP have contributed to focusing interest on the prostate and its diseases.
Development of prostatic diseases is clearly associated with a role of androgens. Castrated males do not develop BPH (3), nor do they develop CAP. The metabolism of testosterone in the prostate includes bioactivation to the more potent dihydrotestosterone (DHT) catalyzed by steroid 5␣-reductase (5␣-red) (4) . Both DHT and testosterone may be oxidized by the 17␤-hydroxysteroid dehydrogenase (17␤-HSD) to 5␣-androstane-3,17-dione and androstenedione, respectively (5) . DHT is further metabolized into 5␣-androstane-3␤, 17␤-diol, and 5␣-androstane-3␣,17␤-diol (6) (Fig.  1 ).
5␣-reductase exists in two forms designated types 1 and 2 (7) (8) (9) . Mutations in the 5␣-red2 gene, leading to a defect 5␣-red2 enzyme, cause a rare form of pseudohermaphroditism. The disorder (5␣-reductase2 deficiency) is manifested by a feminization of male external genitalia and a rudimentary prostate (4) .
The 5␣-red2 isozyme is prostate specific and has an acidic pH optimum (8, 9) , whereas the 5␣-red1 isozyme has a neutral-basic pH optimum and is expressed primarily in the skin and liver and only at relatively low levels in the prostate (7) . Furthermore, the two 5␣-red isoforms have different inhibition profiles, leading to the development of relatively specific inhibitors of the prostatic 5␣-red2 (9, 10), which is the target enzyme in treatment of BPH (11, 12) . Its role in the development of CAP is currently being investigated in a large trial on cancer prevention by the United States National Prostate Cancer Chemoprevention Trial (ongoing) (12) .
The 5␣-red2 enzyme is located mainly in the stromal fraction of the prostate (13) . DHT synthesized in the stroma by 5␣-red2 serves a paracrine role in the induction, proliferation, and differentiation of the adjacent prostatic epithelial cells (14) .
The conversion of testosterone to DHT is a key mechanism in the action of androgens in the prostate and is important in the promotion and progression of prostatic disease. Therefore, it is of great interest to study the converting enzyme in the prostate.
We have developed a sensitive method for quantitation of the gene expression of 5␣-red2 in core needle biopsies of the prostate. The level and variation of the 5␣-red2-specific messenger RNA (mRNA) were studied in groups of patients with clinical symptoms of BPH and CAP. We report significant differences in the gene expression of this enzyme between cancerous tissue and normal tissue.
Materials and Methods

Patients and tissue samples
Tissue biopsies were obtained from patients attending the out-patient clinic of the Department of Urology of the University of Uppsala, Sweden. Patients were referred to the clinic because of lower urinary tract symptoms and/or elevated serum prostatic-specific antigen (s-PSA). Our project was approved by the Ethics Committee of the university. Patients consenting to participate underwent transrectal ultrasound (TRUS) and multiple core biopsies (needle diameter 1.2 mm, notch length 15 mm, weight of biopsy 5-10 mg) from the prostate. One or two biopsies were used for determination of 5␣-red2 mRNA level. These biopsies were snap frozen on dry ice and subsequently kept at Ϫ70 C until analysis. A parallel biopsy was taken for histopathological diagnosis. By use of the TRUS technique it is possible to visualize the trace of the needle and therefore get the second biopsy absolutely adjacent to the first. The close spatial configuration of these two biopsies allows us to assume that the biopsy analyzed is histopathologically equivalent to that of the pathologist's report. Four to six additional diagnostic biopsies were taken from these patients. In some cases, cancer was detected in the additional biopsies. In these cases, the biopsies in the study were considered noncancerous even if the patient had a cancer diagnosis.
A total of 50 biopsies were obtained from 31 patients (median age 72.2, range 57-88 yr). Five patients of these 31 were receiving therapy for their prostatic disease at the time of biopsy; two patients (1 CAP and 1 BPH patient) were on finasteride, two cancer patients were on prednisolone, and one BPH patient was receiving terazosine. We excluded three biopsies for which the histopathology was unclear or missing. The histopathology of the residual 47 biopsies is shown in Table 1 . We excluded prostatic intraepithelial neoplasia (PIN) (n ϭ 4) and prostatitis (n ϭ 2) from the statistical analysis. Included were 41 biopsies: 27 considered to be noncancer and 14 showing cancer. The cancerous biopsies contained 20 -100% (median 94%) cancerous tissue as determined histopathologically in the parallel biopsy.
There were 9 biopsies out of the 27 showing no cancer that were from patients diagnosed with cancer, but the biopsy was obtained from the noncancerous part of the gland.
RNA extraction
Total RNA (totRNA) from small core biopsies (5-10 mg) was extracted using RNeasy total RNA kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol. The totRNA was quantified spectrophotometrically at 260 nm.
PCR of 5␣-red2-specific gene fragment
For the construction of complementary RNA (cRNA) probes a 200 bp fragment was amplified by PCR using 5␣-red2 complementary DNA (cDNA) (2.4 kilobase) in a pBluescript SK vector (Stratagene, La Jolla, CA) as template. Oligonucleotide primers for PCR amplification, which covered codons 591-790 of the 5␣-red2 cDNA were constructed and designed to include an EcoRV restriction site in the 5Ј end of the forward primer, and a SacI restriction site in the 5Ј end of the reverse primer: 5Ј-GAT ATC TGT TTC TGG AGC CAA TTT CCT (forward) and 5Ј-GAG CTC AAA AGA TGA ATG GAA TAA GGG (reverse). PCR was carried out with 100 ng DNA in 100 L buffer, 200 mm deoxynucleotide triphosphates, 2 U Pwo DNA polymerase (Boehringer Mannheim, Mannheim, Germany), and 200 nm of each primer. Temperatures were 94 C for 2 min, followed by 25 cycles of 94 C, 42 C, and 72 C each for 1 min. The predicted size of the PCR product was verified on a 3% agarose gel in TBE-buffer after ethidium bromide staining.
Subcloning of PCR product
The PCR product was purified using QIAquick-spin PCR purification kit (Qiagen GmbH), phosphorylated with T4 polynucleotide kinase . The 5␣-red2-specific fragment was excised with EcoRV and SacI and subcloned into the EcoRV/SacI site of a pBluescript KSϩ plasmid. After transfection, selection, and purification as above, the pBluescript/5␣-red2 construct was used for synthesis of radiolabeled cRNA probes utilized in the hybridization process.
Solution hybridization
cRNA probes were synthezised in vitro utilizing the T7 RNA polymerase promoter and radiolabeled with [
35 S]uridine triphosphate (Amersham International, Buckinghamshire, UK). Synthetic mRNA for construction of standard curves was synthezised from the opposite T3 RNA polymerase promoter.
Hybridization of target RNA was carried out with 35 S-labeled cRNA (20,000 cpm/incubation) in solution (15, 16) . The reaction was performed at 65 C overnight in microcentrifuge vials containing 0.6 m NaCl, 20 mm Tris/HCl, pH 7.5, 4 mm EDTA, 0.1% SDS, 1 mm dithiothreitol, 25% formamide, and 0.5-1.0 g totRNA/vial. After incubation, the samples were treated for 45 min with 1 mL solution containing 40 g RNase A, 2 g RNase T1 (Boehringer) and 100 g salmon sperm DNA.
Radioactive RNA-RNA hybrids protected from RNase digestion were precipitated by addition of 100 L 6 m trichloroacetic acid, collected on a filter (Whatman GF/C, Whatman Intl., Ltd, Maidstone, UK), and quantitated by scintillation counting.
Construction of standard curves and evaluation
Standard curves for calculation of 5␣-red2-specific mRNA in the samples were generated by plotting cpm values (y-axis) vs. synthetic mRNA concentration (x-axis). The 5␣-red2-specific mRNA levels were calculated from the standard curve. Data represent duplicate samples in each experiment. The variation between duplicates was less than Ϯ 5%. Statistical evaluation of the data was made using the Mann-Whitney test.
Results
TRUS core biopsies from the prostate were analyzed for 5␣-red2 gene expression by solution hybridization using 5␣-red2-specific radiolabeled cRNA probe.
The yield of totRNA from the biopsies was approximately 1 g totRNA/mg tissue. The entire 5␣-red2 cDNA (2.4 kb) in a pBluescript (SK-) vector served as template in the PCR reaction for the generation of a 200-bp fragment corresponding to codons 591-790 of the 5␣-red gene (see Materials and Methods). After subcloning, the construct was used for in vitro transcription of a cRNA probe to be used in the hybridization process. The limit of detection was 200 -500 pg synthetic mRNA in the standard curves.
Core needle biopsies from 14 patients clinically diagnosed with BPH and 17 patients with CAP were included in the study. The clinical features of the patients are summarized in Table 2 .
The 5␣-red2-specific mRNA levels varied from 0 -34 amol mRNA/ng totRNA in the 47 biopsies analyzed (Fig. 2) . The limit of detection by the solution hybridization method was 0.5 amol mRNA/ng totRNA. In 7 out of 47 samples 5␣-red2 mRNA levels were undetectable by this method; they are referred to as 0 amol/ng totRNA in Table 1 and Fig. 2 . From 16 patients we obtained duplicate biopsies, with identical histopathology in 13 of the 16 biopsies. The mean difference between duplicate biopsies with identical histopathology was 5.1 amol/ng totRNA (sd Ϯ 4.0). None of the biopsies obtained from the five patients receiving therapy for their prostatic disease were considered extremes with respect to 5a-red2 mRNA expression.
The biopsies were divided into two groups for comparison of 5␣-red2 mRNA levels (noncancer and cancer) depending on the histopathological evaluation of each sample analyzed. There were 14 cancerous biopsies from CAP patients, 18 noncancerous biopsies from BPH patients, and 9 noncancerous biopsies from patients diagnosed with CAP (Table 1 ). In addition there were four biopsies showing PIN and two biopsies showing prostatitis. Significant differences in 5␣-red2 mRNA levels between the cancerous and noncancerous groups were observed, as seen in Table 1 and Fig. 3 . In the 14 biopsies judged to be cancerous, the median 5␣-red2 mRNA levels were 3.5 amol/ng totRNA compared with 12.0 amol/ng totRNA in the 27 biopsies showing no cancer (P ϭ 0.0018). The median 5␣-red2 mRNA level in noncancerous tissue was thus 3.4 times higher than in cancerous specimens (Fig. 3) .
If it is assumed that null values represent failures of technique or degraded mRNA, our analysis still reveals a significant difference between cancerous and noncancerous biopsies (P ϭ 0.0073).
It is of special interest to note that biopsies showing no cancer but which were taken from patients with prostatic carcinoma elsewhere in their prostate (n ϭ 9) had a median concentration of 11.5 amol/ng totRNA, i.e. similar to the levels found in noncancerous biopsies (Table 1 ). This would indicate that lower concentrations of 5␣-red2 mRNA found in cancerous biopsies are caused by the histopathology of cancer in the analyzed cells, rather than a general low value for the prostate harboring cancer.
In addition, we analyzed the material for prostatic size, age of the patient, and serum PSA levels in relation to 5␣-red2 mRNA levels (data not shown). We were unable to find any correlation between the level of 5␣-red2 mRNA and any of those parameters. The study was, however, not designed to detect differences in this respect, because almost all patients were referred to the clinic because of elevated s-PSA levels. Therefore, a comparison between s-PSA and 5␣-red2 mRNA was precluded because of risk of bias.
Discussion
In this study, we describe the quantitation of the mRNA expression of the prostate-specific 5␣-red2 enzyme in core biopsies of the prostate. To our knowledge, this is the first quantitative study of 5␣-red2 mRNA in a large, well-defined, clinical patient material. This new biochemical parameter has not been validated before in relation to the histopathology of the prostate. The method presented is based on solution hybridization and found to be sensitive enough to quantitate levels of 5␣-red2-specific mRNA in small core biopsies of 5-10 mg each. There was a significant difference in the 5␣-red2-specific mRNA levels between cancerous and noncancerous tissue. This finding is consistent with a recently published study by Elo et al. (17) , in which they reported a significantly higher expression of 5␣-red2 mRNA in BPH tissue compared with carcinoma specimens as monitored by Northern blotting. They did not, however, quantitate the specific 5␣-red2 mRNA levels in their study. The lower 5␣-red2 mRNA level in cancerous tissue could be because of the relative lack of stromal cells. This is further supported by the findings that noncancerous tissue from cancer patients had normal 5␣-red2 mRNA levels.
The coefficient of variation of the assay was 5%. As expected (Fig. 2) , a larger variation was observed in the two biopsies obtained from the same prostate. This probably reflects the heterogeneity of the glandular histopathology. In spite of this variation, the difference between the cancerous and noncancerous groups is highly significant.
The design of our study did not allow any comparison between the transcript levels and the activities of the 5␣-red2 enzyme, because approximately 50 mg wet weight tissue is required for the metabolic assay in vitro. However, the present data are in agreement with our previous results from surgical specimens from CAP and BPH prostates with higher DHT formation rates in BPH than in CAP (abstract presented at the 1st Congress of the European Society of Clinical Pharmacology, Paris, 1995). A positive correlation between 5␣-red2 mRNA levels and enzyme activity has also been reported by Thigpen et al. (18) . It is interesting that the immunoblotting studies of 5␣-red2 in CAP and BPH tissue by Thigpen and colleagues did not reveal any difference in protein levels. However, their study was performed on a limited number of tissue samples. Further investigations are required to elucidate the relation between the levels of 5␣-red2 transcript, protein, and the specific enzymatic activity in different types of prostatic tissue and disease.
This study was based on the concept that androgens have a crucial role in the development of CAP and BPH. The ultimate androgen exposure of the prostate depends on a number of factors. In addition to the circulating levels of testosterone and its precursors, the local intraprostatic metabolic pathways influence the total androgen exposure. Whereas the circulating testosterone values decrease with age, the intraprostatic androgen and androgen receptor levels are maintained at an advanced age. 5␣-red2 is only one of several enzymes that take part in the metabolism of testosterone (Fig. 1) . These enzymes include 5␣-red1 and 2; 17␤-HSD1, 2, 3, and 4; 3␣-HSD; and 3␤-HSD1 and 2. Therefore, a more complete picture of the activities of the enzymes involved would be of interest to study in relation to clinical status and treatment of the patient. This is presently a subject of investigation in our laboratory.
Increased knowledge of the intraprostatic enzymes governing androgen metabolism and action in the prostate could be of key value in understanding the pathogenesis of BPH and CAP, the lack of action of androgen deprivation, and the mechanism of hormonal escape. Furthermore, it could contribute to the understanding of drug interactions that influence androgen action in the prostate.
We believe that methods to monitor the effect of various treatments on the prostatic enzymes will be of great value in the development of novel treatment options for CAP and possibly its early diagnosis.
